A dramatic, objective antiandrogen withdrawal response: case report and review of the literature

J Hematol Oncol. 2008 Nov 5:1:21. doi: 10.1186/1756-8722-1-21.

Abstract

Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic prostate cancer. To our knowledge, there have been no reports describing a durable radiologic improvement along with prostate-specific antigen (PSA) with discontinuation of the antiandrogen agent bicalutamide. We report a case in which a dramatic decline of serum PSA levels associated with a dramatic improvement in radiologic disease was achieved with bicalutamide discontinuation.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / physiopathology
  • Aged
  • Androgen Antagonists / therapeutic use*
  • Anilides / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Male
  • Nitriles / therapeutic use*
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / physiopathology
  • Tosyl Compounds / therapeutic use*

Substances

  • Androgen Antagonists
  • Anilides
  • Antineoplastic Agents
  • Nitriles
  • Tosyl Compounds
  • bicalutamide
  • Prostate-Specific Antigen